SARS-CoV-2 - MeSH

Search results

Items: 1 to 20 of 50

<< First< Prev

Page of 3

Select item 20521801.

A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.

Year introduced: 2021(2020)

Select item 20993062.

SARS-CoV-2 variants [Supplementary Concept]

Sequence variants of SARS-COV-2 virus when compared to the reference sequence (NC_045512.2). Many are under investigation for various mutations and their potential impact on COVID-19 (e.g, transmissibility, diagnosis, vaccine effectiveness or clinical presentation or severity). For instance variant B.1.1.7 is characterized by a set of mutations including N501Y on the spike protein which binds human ACE2 PROTEIN. There are more than 900 registered variants as of February 2021.

Date introduced: December 21, 2020

Select item 20522193.

COVID-19 Serological Testing

Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence antibodies specific to SARS-COV-2 or its antigens.

Year introduced: 2021

Select item 21020814.

Baiya SARS-CoV-2 VAX COVID-19 vaccine [Supplementary Concept]

plant (Nicotiana benthamiana) produced SARS-CoV-2 receptor binding domain protein subunit vaccine

Date introduced: May 25, 2022

Select item 20853265.

3C-like proteinase, SARS-CoV-2 [Supplementary Concept]

Date introduced: September 30, 2020

Select item 20890816.

nucleocapsid phosphoprotein, SARS-CoV-2 [Supplementary Concept]

RefSeq NC_045512

Date introduced: October 1, 2020

Select item 20521917.

COVID-19 Vaccines

Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19.

Year introduced: 2021

Select item 21005458.

SARS-CoV-2 recombinant spike protein with delta inulin and CpG-ODN adjuvant vaccine [Supplementary Concept]

Date introduced: August 13, 2021

Select item 20522989.

papain-like protease, SARS-CoV-2 [Supplementary Concept]

Date introduced: October 1, 2020

Select item 205031710.

spike protein, SARS-CoV-2 [Supplementary Concept]

Date introduced: March 19, 2020

Select item 205219611.

COVID-19 Testing

Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of COVID-19 antibodies, SARS-COV-2 antigens or the VIRAL RNA of SARS-COV-2.

Year introduced: 2021

Select item 205217912.

COVID-19

A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.

Year introduced: 2021(2020)

Select item 210323313.

COVID-19 Serotherapy

Transfer of blood plasma derived from patients who have recovered from COVID-19 to non-immune hosts.

Year introduced: 2023 (2020)

Select item 210213114.

NS13 protein, SARS-CoV-2 [Supplementary Concept]

GenBank QHD43415

Date introduced: June 2, 2022

Select item 208532915.

NSP12 protein, SARS-CoV-2 [Supplementary Concept]

Date introduced: October 1, 2020